Cancer drug regorafenib tested to halt bone sarcoma spread
NCT ID NCT02389244
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests whether the drug regorafenib can stop or slow the growth of metastatic bone sarcomas (cancers that started in bone and spread). 163 patients with osteosarcoma, Ewing sarcoma, chondrosarcoma, or chordoma are randomly assigned to receive regorafenib or a placebo. The main goal is to see how many patients have no disease progression after a set time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Regorafenib (Stivarga), a cancer drug taken as tablets
What this could lead to
If it works, this could offer a new treatment option to slow the growth of metastatic bone sarcomas.
What could go wrong
This is a mid-stage trial with a modest size, so results may not confirm benefit. Regorafenib can cause side effects like fatigue, diarrhea, and liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHORDOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Bretonneau
Tours, 37000, France
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre Eugene Marquis
Rennes, 35042, France
-
Centre Francois Baclesse
Caen, 14176, France
-
Centre Georges Francois Leclerc
Dijon, 21079, France
-
Centre Léon Berard
Lyon, 69373, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Gustave Roussy
Villejuif, 94800, France
-
Hopital Jean Monjoz
Besançon, 25030, France
-
Hôpital Cochin
Paris, 75014, France
-
ICM Val d'Aurelle
Montpellier, 34298, France
-
Institut Bergonie
Bordeaux, 33076, France
-
Institut Claudius Regaud
Toulouse, 31052, France
-
Institut Curie
Paris, France
-
Institut Paoli Calmettes
Marseille, 13273, France
-
Institut de Cancérologie Lucien Neuwirth (ICLN)
Saint-Priest-en-Jarez, 42270, France
-
Institut de cancerologie de l'ouest site Rene Gauducheau
Saint-Herblain, 44805, France
-
Institut de cancerologie de lorraine alexis Vautrin
Vandœuvre-lès-Nancy, 54519, France
-
La Timone University Hospital
Marseille, 13385, France